BuyseM., Zeleniuch-JacquotteA., ChalmersT.C.: Adjuvant therapy of colorectal cancer: why we still don't know.JAMA,259: 3571–3578, 1988.
2.
WolmarkN., FisherB., RocketteH.: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01.J Natl Cancer Inst,80: 30–36, 1988.
3.
MoertelC.G., FlemingT.R., MacDonaldJ.S.: Fluorouracil + levamisol as adjuvant treatment after resected colon carcinoma.N Engl J Med,322: 352–358, 1990.
4.
NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer.JAMA, 264: 1444–1450, 1990.
5.
International Multicentric Pooled Analysis of Colon Cancer Trials Investigators - IMPACT: Efficacy of adjuvant 5FU and folinic acid in colon cancer.Lancet,345: 939–944, 1995.
6.
International Multicentric Pooled Analysis of B2 Colon Cancer Trials Investigators - IMPACT: B2: efficacy of adjuvant 5FU and folinic acid in B2 colon cancer.J Clin Oncol,17: 1356–1363, 1999.
7.
MamounasE., WielandS., WolmarkN.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes B vs Dukes C colon cancer: results from 4 national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03, C-04).J Clin Oncol,17: 1349–1355, 1999.
8.
DeGramontA., BanziM., NavarroJ.: Oxali-platin/5FU/LV in adjuvant colon cancer: results of the international randomized MOSAIC trial.Proc ASCO,22: A1015, 2003.
9.
CunninghamD., JamesR.: Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.Eur J Cancer,37; 826–834, 2001.
10.
GoldbergR.M., MortonR.F., SargentD.J.: N9741: oxaliplatin or CPT11 + 5FU/LV in advanced colorectal cancer. Updated efficacy and qualità of life data from an intergroup study.Proc ASCO,22: A1009, 2003.
11.
RothenbergM.L., OzaA.M., BurgerB.: Final results of a phase III trial of 5FU/LV vs oxaliplatin vs the combination in patients with metastatic colorectal cancer following irinotecan, 5FU/LV.Proc ASCO,22: A1011, 2003.
12.
ColucciG., MaielloE., GebbiaV.: Preliminary results of a randomized multicenter trial of the Gruppo Oncologico Italia Meridionale (GOIM) comparing FOLFIRI vs FOLFOX in advanced colorectal cancer (ACC) patients.Proc ASCO,22: A1021, 2003.
13.
AndrèT., FigerA., CervantesA.: FOLFOX7 compared to FOLFOX4: preliminary results of the randomized OPTIMOX study.Proc ASCO,22: A1016, 2003.
14.
BornerM., MuellerS., RothA.: Phase II study of capecitabine + oxaliplatin in first line and second line treatment of advanced or metastatic colorectal cancer.Proc ASCO,20: A137, 2001.
15.
Diaz-RubioE., EvansJ., TaberneroJ.: Phase I study of capecitabine in combination with oxaliplatin in patients with advanced or metastatic solid tumors.Proc ASCO,19: 198A, 2000.
16.
Van CutsemE., TwelvesC., TabarneroJ.: XELOX: mature results of a multinational phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients with MCRC.Proc ASCO,22: A1023, 2003.
17.
LouvetC., LabiancaR., HammelP.: GEMOX in non respectable pancreatic adenocarcinoma: interim results of a GERCOR/GISCAD Intergroup phase III trial.Proc ASCO,22: A1004, 2003.
18.
Maindrault-GoebelF., SelleF., RosmorducO.: A phase II study of GEMOX in advanced biliary adenocarcinoma: final results.Proc ASCO,22: A1178, 2003.
